Extended-release oral dosage forms for poorly soluble amine drugs
Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling membrane. Such dosage forms allow for the consistent release of the active agent in both gastric pH conditions and in the intestine. Methods of making such dosage forms are also provided.
1. An extended-release oral dosage form for poorly soluble amine compounds comprising,
(a) a core having an ionizable compound, wherein the ionizable compound is an organic acid, wherein the organic acid is selected from the group consisting of citric acid, maleic acid and combinations thereof;
(b) a barrier layer coating the core;
(c) a mantle of a matrix having a poorly soluble amine compound and at least one amphiphilic polymer, wherein the amphiphilic polymer is selected from the group consisting of polyethylene glycol 6000/vinylcaprolactam/vinyl acetate 13/57/30, d-α-tocopheryl polyethyleneglycol 1000 succinate (Vitamin E-TPGS), and combinations thereof; and
(d) a release-rate controlling layer coating the mantle;
wherein the ionizable compound and the amphiphilic polymer are in amounts sufficient to provide synergistic solubility effect.
2. The ectended-release oral dosage form of claim 1 , wherein the amphiphilic polymer has an HLB of at least about 7.0.
3. The ectended-release oral dosage form of claim 1 , wherein the poorly soluble amine compound is selected from the group consisting of paliperidone, donepezil, tamsulosin, methylphenidate, olanzapine and dipyridamole.
4. The ectended-release oral dosage form of claim 1 , wherein the poorly soluble amine compound has a pKa from about 5 to about 11 and a nitrogen content from about 3% to about 23% of the total molecular weight of the poorly soluble amine compound.
5. The ectended-release oral dosage form of claim 1 , wherein the poorly soluble amine compound has a pKa from about 8 to about 9 and a nitrogen content from about 8% to about 15% of the total molecular weight of the poorly soluble amine compound.
6. The ectended-release oral dosage form of claim 1 , wherein the release-rate controlling layer is selected from the group consisting of hydrophobic polymers selected from ethylcellulose, methylcellulose, propylcellulose, ethylmethylcellulose, cellulose acetate, cellulose acetate propionate or ethyl acrylate-methyl methacrylate copolymer, enteric polymers, methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl methacrylate copolymer, hydroxypropyl methylcelluose phthalate, hydroxypropyl methylcellulose acetate succinate, hydrophilic polymers, hydroxypropyl methylcellulose, hydroxypropyl cellulose, povidone, copovidone, polyethylene glycol, triacetin, dibutyl sebacate, triethyl citrate, and combinations thereof.
7. An extended-release oral dosage form for poorly soluble amine compounds comprising,
(a) a core having an ionizable compound, and a mantle of a matrix having an amphiphilic polymer and a poorly soluble amine compound, wherein the ionizable compound comprises an organic acid,
wherein the organic acid is selected from the group consisting of citric acid, maleic acid and combinations thereof,
wherein the amphiphilic polymer is selected from the group consisting of polyethylene glycol 6000/vinylcaprolactam/vinyl acetate 13/57/30, d-α-tocopheryl polyethyleneglycol 1000 succinate (Vitamin E-TPGS), and combinations thereof and the amphiphilic polymer has an HLB of at least about 7.0;
wherein the ionizable compound and the amphiphilic polymer are in amounts sufficient to provide synergistic solubility effect; and
(b) a release-rate controlling membrane selected from the group consisting of a hydrophobic polymer, an enteric polymer, a hydrophilic polymer, a plasticizer and combinations thereof, wherein the core is covered by the release-rate controlling membrane.